Press Releases

Blend Therapeutics Scientific Co-Founder Professor Robert Langer awarded
National Medal of Technology and Innovation

Professor Langer NMTI

WATERTOWN, MA – February 4, 2013 – Blend Therapeutics, Inc., a biopharmaceutical company discovering novel medicines by integrating its novel drug discovery and nanotechnology, announced today that its scientific co-founder, Robert S. Langer, ScD, David H Koch Institute Professor at Massachusetts Institute of Technology, received the National Medal of Technology and Innovation at the White House from President Barack Obama at a ceremony on Friday, February 1, 2013, in Washington, D.C. 

“It’s a privilege to work closely with Bob Langer in discovering and developing Blend’s innovative cancer therapies.  Throughout his entire career, Bob has had an unparalleled track record of driving significant scientific advances.  We are very fortunate to have the insight of one of only few scientists in history to be selected for both the National Medal of Science and the National Medal of Technology and Innovation,” said Mark Iwicki, President and Chief Executive Officer of Blend Therapeutics. “Bob has been instrumental in supporting Blend as we pioneer the development of new classes of medicines. I’m thrilled for Bob to receive this highly prestigious award and to be honored for his many contributions with a reach the world has seen only a few times in its modern history.”

“I’m very excited about working with Blend on integrating our novel drug discovery approaches with nanotechnology to make what I hope will be truly significant improvements in the standard of medical care," said Professor Robert Langer, who serves on the board of directors and scientific advisory board of Blend Therapeutics.

Professor Langer previously received the National Medal of Science at the White House from President George W. Bush in 2007 and he is the seventh individual to have received both medals in history. Professor Stephen J. Lippard, another scientific co-founder of Blend Therapeutics and the Arthur Amos Noyes Professor of Chemistry at the Massachusetts Institute of Technology, also received the National Medal of Science from President George W. Bush in 2006.

About Blend Therapeutics
Blend Therapeutics is a biopharmaceutical company discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties.  Our proprietary technology, assets and expertise are built around an integrative R&D process that brings together our new-molecule drug discovery engine and our patented nanoparticle engineering platform.   Using its drug discovery approach, Blend has created a pipeline of new molecules and is initially focused on developing innovative cancer drugs. The company was founded by three leaders in the fields of chemistry and nanomedicine from the Brigham and Women’s Hospital (BWH)–Harvard Medical School (HMS), and Massachusetts Institute of Technology (MIT): Dr. Omid Farokhzad of BWH–HMS, and Dr. Robert Langer and Dr. Stephen J. Lippard of MIT. Blend has attracted top-tier investors including Flagship Ventures, NanoDimension, and New Enterprise Associates. For more information, visit

About the National Medal of Technology and Innovation
The National Medal of Technology and Innovation (NMTI) is the nation’s highest honor for technological achievement, bestowed by the president of the United States on America's leading innovators. The medal is awarded annually to individuals, teams (up to four individuals), companies or divisions of companies for their outstanding contributions to America’s economic, environmental and social well-being. The purpose of the National Medal of Technology and Innovation is to recognize those who have made lasting contributions to America's competitiveness, standard of living, and quality of life through technological innovation, and to recognize those who have made substantial contributions to strengthening the nation's technological workforce. For more information, visit


#  #  #

For more information, please contact:
Kathryn Morris
The Yates Network